Compare IRMD & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRMD | ETW |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.1M |
| IPO Year | 2014 | N/A |
| Metric | IRMD | ETW |
|---|---|---|
| Price | $99.25 | $9.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $72.00 | N/A |
| AVG Volume (30 Days) | 89.1K | ★ 284.6K |
| Earning Date | 02-12-2026 | 01-01-0001 |
| Dividend Yield | 0.69% | ★ 8.61% |
| EPS Growth | ★ 13.00 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $80,511,268.00 | N/A |
| Revenue This Year | $15.17 | N/A |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | $59.98 | ★ N/A |
| Revenue Growth | ★ 12.91 | N/A |
| 52 Week Low | $47.48 | $6.96 |
| 52 Week High | $100.39 | $8.49 |
| Indicator | IRMD | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 59.90 |
| Support Level | $97.39 | $9.24 |
| Resistance Level | $100.01 | $9.34 |
| Average True Range (ATR) | 2.31 | 0.05 |
| MACD | -0.23 | 0.00 |
| Stochastic Oscillator | 83.45 | 80.56 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.